Form 4: Director Sridhar Kosaraju Receives 10x Genomics RSU Grant
Statement of Changes in Beneficial Ownership
Director Sridhar Kosaraju was granted 8,829 restricted stock units by 10x Genomics, Inc. as part of his ongoing service.
Summary
- Director Sridhar Kosaraju acquired 8,829 restricted stock units (RSUs) on June 4, 2026.
- Each RSU represents a contingent right to receive one share of Class A Common Stock upon vesting.
- The RSUs vest in quarterly installments over one year, starting from May 21, 2026, contingent on continued service.
- Following this transaction, the director's direct beneficial ownership increased to 65,278 shares.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation, which carries a neutral sentiment.
Positives
- The grant aligns the director's interests with long-term shareholder value through equity-based compensation.
Negatives
- None identified.
Risks
- Vesting is subject to the director continuing as a service provider to the company.
Future Outlook
The RSUs will vest in equal quarterly installments over a one-year period, provided the director remains a service provider.
Industry Context
StockSavvy.ai notes that equity grants to directors are standard corporate governance practices in the biotechnology and life sciences sector to ensure alignment between board members and shareholders.
Comparison to Industry Standards
- The use of RSU-based compensation for board members is consistent with standard practices for NASDAQ-listed life sciences companies.
- The vesting schedule of one year is relatively standard for director equity retention programs.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Power of Attorney | Appointment of Randy Wu and James Bryant as attorneys-in-fact for SEC filings. | 2026-03-04 | Standard administrative procedure to facilitate timely regulatory compliance. |
Related Party Transactions
- The director maintains indirect ownership of 3,000 shares through the Kosaraju Family Trust.
Stakeholder Impact
- Shareholders may view the equity grant as a standard alignment of director incentives.
Next Steps
- Quarterly vesting of the granted RSUs starting from May 21, 2026.
Key Dates
| Date | Description |
|---|---|
| 2014-06-21 | Date of the Kosaraju Family Trust establishment. |
| 2026-03-04 | Execution date of the Power of Attorney. |
| 2026-05-21 | Start date for RSU vesting measurement. |
| 2026-06-04 | Date of the RSU grant transaction. |
| 2026-06-08 | Filing date of the Form 4. |
Keywords
10x Genomics, TXG, Director, Insider Transaction, Equity Compensation, RSU, Form 4
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.